Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nucana ( (NCNA) ) has provided an announcement.
On June 18, 2025, NuCana plc received a notice from Nasdaq indicating that its American Depositary Shares (ADSs) had fallen below the $1.00 minimum bid price requirement for 30 consecutive trading days. The company was given until December 15, 2025, to regain compliance. However, on July 8, 2025, NuCana received a second notice from Nasdaq as the ADSs closed below $0.10 for 10 consecutive trading days, putting the company at risk of delisting. NuCana plans to request a hearing to prevent suspension or delisting, which will temporarily halt any such actions.
The most recent analyst rating on (NCNA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc operates in the pharmaceutical industry, focusing on the development of novel cancer treatments. The company is known for its proprietary ProTide technology, which aims to improve the efficacy and safety of existing chemotherapy drugs.
Average Trading Volume: 157,236,683
Technical Sentiment Signal: Sell
Current Market Cap: $19.04M
Find detailed analytics on NCNA stock on TipRanks’ Stock Analysis page.